Inhibitor Transient Receptor Potential Vanilloid Type 1: Penggunaan Topikal pada Berbagai Dermatosis

Parikesit Muhammad; Larisa Paramitha Wibawa; Windy Keumala Budianti; Lili Legiawati; Sri Linuwih Menaldi; Dewi Selvina Rosdiana

doi:10.36452/JMedScientiae.v3i2.3179

Authors

Parikesit Muhammad Departement of Dermatology and Venereology, Cipto Mangunkusumo General Hospital, Faculty of Medicine, University of Indonesia
Larisa Paramitha Wibawa Departemen Dermatologi dan Venereologi, Fakultas Kedokteran Universitas Indonesia, Rumah Sakit Umum Pusat Nasional dr. Cipto Mangunkusumo, Jakarta, Indonesia
Windy Keumala Budianti Departemen Dermatologi dan Venereologi, Fakultas Kedokteran Universitas Indonesia, Rumah Sakit Umum Pusat Nasional dr. Cipto Mangunkusumo, Jakarta, Indonesia
Lili Legiawati Departemen Dermatologi dan Venereologi, Fakultas Kedokteran Universitas Indonesia, Rumah Sakit Umum Pusat Nasional dr. Cipto Mangunkusumo, Jakarta, Indonesia
Sri Linuwih Menaldi Departemen Dermatologi dan Venereologi, Fakultas Kedokteran Universitas Indonesia, Rumah Sakit Umum Pusat Nasional dr. Cipto Mangunkusumo, Jakarta, Indonesia
Dewi Selvina Rosdiana Departemen Farmakologi Klinik dan Teurapetik, Fakultas Kedokteran Universitas Indonesia, Jakarta, Indonesia

DOI:

https://doi.org/10.36452/JMedScientiae.v3i2.3179

Keywords:

topical, transient receptor potential vanilloid type 1 inhibitor, receptor

Abstract

Transient receptor potential vanilloid type 1 (TRPV1) plays an important role in the pathophysiology of pruritus and pain. TRPV1 inhibitors can reduce the sensation of itching and pain by blocking nociceptive signals from peripheral nerve fibers to the central nervous system. Topical TRPV1 inhibitors is also thought to improve skin barrier function. Therefore, TRPV1 inhibitors are considered as potential therapy in various dermatoses. Topical TRPV1 inhibitors that are currently being studied are asivatrep for atopic dermatitis and trans-4-tert-butylcyclohexanol for various dermatoses associated with sensitive skin. Further studies with better quality and longer duration are needed to assess the efficacy and safety profile of TRPV1 inhibitors.